Actively Recruiting
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
Led by Kelly McMasters · Updated on 2025-10-30
30
Participants Needed
1
Research Sites
323 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
CONDITIONS
Official Title
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with clinical or tissue-confirmed Stage III-IV melanoma starting or continuing adjuvant pembrolizumab with no active disease
- Treatment naive or last treatment at least 6 months before enrollment
- Age 18 years or older
- Ability to take pills by mouth
- ECOG performance status between 0 and 3
- Able to understand and willing to sign informed consent
- Eligible regardless of racial or ethnic group
You will not qualify if you...
- History of allergic reactions to beta-glucan
- Receiving continuous or ongoing immunosuppressive therapy
- Uncontrolled illnesses such as autoimmune disease, active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social conditions limiting study compliance
- Serious autoimmune toxicity or disease recurrence during the 6-week study period
- Diagnosis of mucosal melanoma
- Having other current or recent malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Louisville
Louisville, Kentucky, United States, 40202
Actively Recruiting
Research Team
M
Matthew Woeste, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here